Kings Path Partners’s GSK GSK Stock Holding History

Kings Path Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$4.32K	–	311
2025 Q3	$4.32K	Buy	+100	New	+$3.91K	﹤0.01%	262

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kings Path Partners's GSK Position: Q4 2025 in Review

Kings Path Partners sold out of GSK (GSK) in Q4 2025, closing a stake of 100 shares — an estimated $4.32K sold.

Kings Path Partners first reported a position in GSK in Q3 2025 and held it in 1 quarter. The position peaked at $4.32K in Q3 2025. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Kings Path Partners reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Kings Path Partners sold 100 GSK shares in Q4 2025, an estimated $4.32K.
Kings Path Partners first reported a position in GSK in Q3 2025 and held it in 1 quarter.
Kings Path Partners's GSK position peaked at $4.32K in Q3 2025.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Kings Path Partners's 13F filing for Q4 2025, filed 14 Jul 2026.